|
|
|
News For ACT;TEVA;ENDP;COV;ABT From The Last 14 Days Check below for free stories on ACT;TEVA;ENDP;COV;ABT the last two weeks. |
|
|
| June 12, 2013 | | 08:28 EDT |  | TEVA | Teva to pay $1.6B to settle with Pfizer, Nycomed over generic Protonix
 Subscribe for More Information | | | 08:23 EDT | | TEVA | Teva, Active Biotech announces results of Phase IIa study of laquinimod
Subscribe for More Information | | | 08:09 EDT | | TEVA | Teva's Laquinimod for lupus reports positive Phase II results
Subscribe for More Information | | | 08:02 EDT | | TEVA | Pfizer wins $2.15B settlement from Teva and Sun for patent infringement
Subscribe for More Information | | | 07:08 EDT |  | TEVA, ACT | Drugstores ready access changes to Plan B pill, WSJ reports
Drugstores (CVS, RAD, WAG) are preparing to change how they stock and sell a widely used emergency contraceptive after the Obama administration agreed to allow the pill to be sold over the counter to customers of all ages. Sold primarily under the brand name Plan B (TEVA, ACT, PRGO), the pill is currently stocked behind pharmacy counters, reports the Wall Street Journal.Reference Link | | | 06:53 EDT | | ACT | Columbia Laboratories announces class action lawsuit against company dismissed
Subscribe for More Information | | | 06:05 EDT | | TEVA, ACT | On the Fly: Periodicals Wrap-Up
WALL STREET JOURNAL: The tectonic plates of the world economy are shifting, moving the yield on the 10-year Treasury to the highest level in more than a year and shaking financial markets. Now, some constants are being questioned in markets, triggering paroxysms in stocks, bonds, commodities and the currencies of emerging markets, the Wall Street Journal reports...Drugstores (CVS, RAD, WAG) are preparing to change how they stock and sell a widely used emergency contraceptive after the Obama administration agreed to allow the pill to be sold over the counter to customers of all ages. Sold primarily under the brand name Plan B (TEVA, ACT, PRGO), the pill is currently stocked behind pharmacy counters, the Wall Street Journal reports...REUTERS: If currency turbulence in emerging markets becomes a full-scale investor flight, the Fed may have a new headache in deciding when to slow its dollar printing policy. The link between U.S. monetary policy and currency runs on the other side of the world could be tighter than many assume, Reuters reports...Toyota Motor (TM) said it’s unlikely to recapture its peak market share it held four years ago in the U.S. (GM, F), its biggest market, the latest sign the carmaker is shifting to improving quality from aggressively expanding sales, Reuters reports...BLOOMBERG: Exchange executives (NYX, NDAQ), long shielded from legal scrutiny in the U.S., have been put on notice that may be changing after federal regulators fined CBOE Holdings (CBOE) $6M for unprecedented lapses in supervision, Bloomberg reports...Borealis Infrastructure Management and its Kuwaiti-British partners abandoned their $8.3B bid for the U.K. water utility Severn Trent (SVTRY) as the offer deadline expired, Bloomberg reports. | | | June 11, 2013 | | 17:59 EDT | | ACT | Actavis, Medicines360 announce partnership
Medicines360, a non-profit pharmaceutical company, and Actavis, announced a partnership to support Medicines360’s mission to reduce cost as a barrier to accessing women’s birth control. The Medicines360 and Actavis partnership will make the IUD available in the U.S. commercially and at a very low price in U.S. public sector clinics. As part of this agreement, Actavis has licensed the U.S. commercial rights for the Medicines360 LNG20 Intrauterine Device, or IUD. Medicines360 retains rights to market the product in the U.S. public sector, including family planning clinics that provide services to low-income women. LNG20, originally developed by Uteron Pharma S.P.R.L. in Belgium, is designed to initially deliver 20 mcg of levonorgestrel per day for the indication of long term contraception, and is currently in Phase III clinical trials in the United States. Pending FDA approval, the LNG20 IUD could be launched in the U.S. as early as 2014. | | | 10:14 EDT | | ACT | Actavis acquires U.S. commercial rights for LNG20 IUD
Medicines360, a non-profit pharmaceutical company, and Actavis announced a partnership to support Medicines360’s mission to reduce cost as a barrier to accessing women’s birth control. The Medicines360 and Actavis partnership will make the IUD available in the U.S. commercially and at a very low price in U.S. public sector clinics. As part of this agreement, Actavis has licensed the U.S. commercial rights for the Medicines360 LNG20 Intrauterine Device. Medicines360 retains rights to market the product in the U.S. public sector, including family planning clinics that provide services to low-income women. LNG20 is currently in Phase III clinical trials in the United States. Pending U.S. Food and Drug Administration approval, the LNG20 IUD could be launched in the U.S. as early as 2014, the companies said. | | | 09:33 EDT | | ABT | Abbott begins Absorb BVS clinical trial in Japan
Subscribe for More Information | | | | 07:30 EDT |  | ACT | Actavis added to Analyst Focus List at JPMorgan
JPMorgan added Actavis to its Analyst Focus List citing earnings growth potential following the acquisition of Warner Chilcott. The firm has an Overweight rating on the stock with a $150 price target. | | | 05:50 EDT | | ACT, TEVA | U.S. to now comply with ruling on morning-after pill, WSJ reports
In a reversal, the U.S. government said it would allow emergency contraceptive Plan B to be sold in drugstores without restrictions and would end an appeal in a long-running court case, reports the Wall Street Journal. Reference Link | | | June 10, 2013 | | 07:20 EDT |  | TEVA | Biomed to host a conference
Subscribe for More Information | | | June 7, 2013 | | 08:11 EDT | | ACT | Actavis confirms generic Diprivan patent challenge
Actavis confirmed that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Propofol Injection 10mg/mL. Actavis' ANDA product is a generic version of Fresenius Kabi's Diprivan, which is an intravenously administered sedative and anesthetic. Fresenius Kabi USA filed suit against Actavis on June 6 in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain U.S. patents. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. | | | June 6, 2013 | | 10:01 EDT |  | ENDP | On The Fly: Analyst Downgrade Summary
Subscribe for More Information | | | 10:01 EDT |  | ENDP | On The Fly: Analyst Upgrade Summary
Subscribe for More Information | | | 08:30 EDT | | ACT, TEVA | Federal appeals court orders access to contraceptive, WSJ reports
Subscribe for More Information | | | 08:28 EDT | | ACT | Actavis confirms generic Safyral patent challenge
Actavis confirmed last night that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Drospirenone/Ethinyl Estradiol/Levomefolate Calcium Tablets And Levomefolate Calcium Tablets. Actavis' ANDA product is a generic version of Bayer's Safyral, which is approved to prevent pregnancy in women who elect to use an oral contraceptive, and to provide a daily dose of folate supplementation. Merck & CIE, Bayer Pharma AG and Bayer Healthcare Pharmaceuticals filed suit against Actavis on June 4 in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. patent no. 6441168. The lawsuit resulted in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court. Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Safyral and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity, the company said. | | | 08:03 EDT | | ABT | Abbott shares compelling, says Wells Fargo
Subscribe for More Information | | | 07:53 EDT | | ENDP | Endo Health upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information | | |
|
|
|
|
|
|
